Abstract: The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein.
Type:
Grant
Filed:
December 28, 2012
Date of Patent:
December 1, 2015
Assignees:
Institut Pasteur, Ecole Nationale Veterinaire D'Alfort, Institut Curie, Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique (INRA)
Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), while preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
Type:
Grant
Filed:
December 4, 2012
Date of Patent:
November 24, 2015
Assignee:
NOVARTIS AG
Inventors:
Winfried Elis, Seth Ettenberg, Andrew Paul Garner, Nicole Haubst, Xizhong Huang, Christian Carsten Silvester Kunz, Elizabeth Anne Reisinger Sprague, Qing Sheng
Abstract: The present invention relates to a mutant of MITF which is useful as a marker for predisposition to the development of cancer and to uses thereof in diagnosis and preventive treatments, sumoylation being reduced or absent in this mutant.
Type:
Grant
Filed:
December 21, 2010
Date of Patent:
November 24, 2015
Assignees:
INSTITUT GUSTAVE ROUSSY, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE SOPHIA NICE ANTIPOLIS
Inventors:
Robert Ballotti, Corine Bertolotto, Brigitte Bressac De Paillerets, Mahaut De Lichy, Fabienne Lesueur
Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Type:
Grant
Filed:
September 21, 2010
Date of Patent:
November 17, 2015
Assignee:
GENMAB A/S
Inventors:
Michel De Weers, Yvo Graus, Judith Oprins, Paul Parren, Jan Van De Winkel, Martine Van Vugt
Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.
Type:
Grant
Filed:
November 12, 2014
Date of Patent:
November 10, 2015
Assignee:
Thrasos Innovation, Inc.
Inventors:
William D. Carlson, Peter C. Keck, Michael Sworin, Dattatreyamurty Bosukonda
Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
Abstract: The invention relates to novel, Frizzled-like, immunogenic peptides, useful for the stimulation of an immune response against various cancer types, particularly colon rectal carcinoma.
Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
Type:
Grant
Filed:
March 1, 2011
Date of Patent:
October 6, 2015
Assignee:
MacroGenics, Inc.
Inventors:
Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen
Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.
Abstract: Methods for assessing a pathological condition in a subject include measuring one or more markers where a difference is indicative of acute lymphoblastic leukemia (ALL) or a predisposition to ALL, uses and compositions are disclosed.
Type:
Grant
Filed:
June 13, 2013
Date of Patent:
September 22, 2015
Assignee:
The Ohio State University Research Foundation
Abstract: Described herein are antibodies, and antigen-binding fragments thereof, that are specific for tumor endothelial marker 1 (TEM-1), related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing TEM-1-expressing cancers (such as melanoma, sarcoma, bladder cancer, gastric cancer, hepatocellular cancer, or colon cancer) using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of TEM-1 in a biological sample derived from a subject and comparing this level with the level of TEM-1 in a known standard or reference sample.
Abstract: The invention provides peptides, portions and derivatives thereof, that are useful for reducing cell migration, and for reducing symptoms of pathological diseases that are associated with undesirable cell migration, and in particular MMP-induced cell migration. This invention also provides peptides that are useful for detecting (e.g., imaging) cancers.
Type:
Grant
Filed:
April 19, 2011
Date of Patent:
September 15, 2015
Assignee:
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Abstract: The invention relates to the field of organ and biological tissue preservation and in particular to solutions for use in preserving organs and/or tissues prior to transplanting into a subject.
Type:
Grant
Filed:
June 28, 2007
Date of Patent:
September 15, 2015
Assignee:
University Court of the University of Edinburgh
Abstract: The present invention relates to polypeptides, nucleic acids and pharmaceutical compositions suitable for use in the treatment of ErbB2 dependent-cancers, in particular of tumors overexpressing ErbB2 or expressing mutated forms of the ErbB2 gene.
Abstract: Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA.
Type:
Grant
Filed:
March 1, 2011
Date of Patent:
September 8, 2015
Assignee:
Caris Life Sciences Switzerland Holdings GmbH
Inventors:
David D. Halbert, George Poste, Michael Klass, David Spetzler, Traci Pawlowski, Daniel Holterman
Abstract: This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.
Type:
Grant
Filed:
January 30, 2014
Date of Patent:
September 1, 2015
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Inventors:
William R. Taylor, Jonathan J. Harrington, Patrick S. Quint, Hongzhi Zou, Harold R. Bergen, III, David I. Smith, David A. Ahlquist
Abstract: The present invention provides a pharmaceutical agent or composition containing one or more peptides having the amino acid sequence of SEQ ID NO: 1 or 2, or one or more polynucleotides encoding such a peptide formulated for the treatment and/or prevention of cancer in a subject whose HLA-A antigen is HLA-A0206. Furthermore, the present invention provides a method of inducing CTL and antigen-presenting cells using such peptides, polynucleotides or pharmaceutical agents.
Abstract: The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.
Type:
Grant
Filed:
December 10, 2012
Date of Patent:
September 1, 2015
Assignees:
ARIZONA BOARD OF REGENTS ON BEHALF OF UNIVERSITY OF ARIZONA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION
Inventors:
Eugene W. Gerner, Jason A. Zell, Christine E. McLaren, Frank L. Meyskens, Jr., Hoda Anton-Culver, Patricia A. Thompson
Abstract: The present invention relates to antibodies against specific domains of Olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the Olfml3 antagonists.
Type:
Grant
Filed:
January 17, 2014
Date of Patent:
August 4, 2015
Assignee:
Research Development Foundation
Inventors:
Beat A. Imhof, Marijana Miljkovic-Licina, Philippe Hammel
Abstract: It is disclosed herein that condroitin sulfate proteoglycan 4 (CSPG4), also known as high molecular weight melanoma associated antigen, is overexpressed on basal breast carcinoma cells (BBC), specifically triple negative basal breast carcinoma cells (TNBC). Methods for detecting basal breast cancer in a subject are disclosed. Methods are also disclosed for inhibiting the growth of a basal breast cancer cell. These methods include contacting the basal breast cancer cell with an effective amount of an antibody that specifically binds CSPG4. Additional treatment methods, and the use of antibody panels, are also described herein.
Type:
Grant
Filed:
June 18, 2013
Date of Patent:
August 4, 2015
Assignee:
University of Pittsburgh—Of the Commonwwealth System of Higher Education